![]() ![]() To date, the only options for child brain cancer are intensive radiation and chemotherapy and, in cases where possible, surgery. Having established a foothold in adult brain cancer drug development, Kazia’s management is well positioned to extend its platform into child brain cancer. Natural extension into child brain cancer This progress in adult brain cancer trials provides Kazia with the experience and capabilities that would likely make an extension into child brain cancer, an untapped market opportunity, a natural move. With multiple programs expected to read out in CY22, including studies assessing paxalisib in brain metastases (BMs) in Q2 CY22 (one Phase I and two Phase II trials, sponsored by Sloan-Kettering, the NIH and Dana-Farber, respectively) and interim data from the EVT801 Phase I study in H2 CY22, we foresee several potential inflection points for the company in the coming months. The first site outside of the United States (in Canada) became operational in November 2021 and site expansion into Europe and China is planned for Q2 CY22 (partner Simcere’s investigative new drug application was approved in China in January 2022). ![]() ![]() The company recruited its first patient in the paxalisib arm of the GBM AGILE study in January 2021 and remains on track to recruit approximately 200 patients, with data expected in H2 CY23. Kazia continues to progress its main asset, paxalisib, in addressing adult brain cancer. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |